Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Barr body

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44334   clinical trials with a EudraCT protocol, of which   7366   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    16 result(s) found for: Barr body. Displaying page 1 of 1.
    EudraCT Number: 2008-000252-28 Sponsor Protocol Number: SHCVOLT1 Start Date*: 2009-03-13
    Sponsor Name:Cambridge University Hospitals NHS Foundation Trust
    Full Title: A Multi-Centre Prospective Controlled Trial Comparing Calcineurin Inhibitor Monotherapy With Sirolimus Monotherapy in Hepatitis C Infected Patients with Hepatic Fibrosis Following Liver Transplanta...
    Medical condition: Patients who have undergone liver transplantation and are infected with Hepatitis C virus.
    Disease: Version SOC Term Classification Code Term Level
    9.1 10052779 Transplant rejections HLT
    9.1 10024970 Respiratory tract infections HLGT
    9.1 10046577 Urinary tract infections HLT
    9.1 10001032 Acute pyelonephritis LLT
    9.1 10040072 Septicaemia LLT
    9.1 10019972 Herpes viral infections HLT
    9.1 10028440 Mycobacterial infectious disorders HLGT
    9.1 10015107 Epstein-Barr viral infections HLT
    9.1 10011831 Cytomegalovirus infection LLT
    9.1 10019974 Herpes zoster LLT
    9.1 10058872 Fungal sepsis LLT
    9.1 10040808 Skin cancer PT
    9.1 10051358 Post transplant lymphoproliferative disorder LLT
    9.1 10043555 Thrombocytopenias HLT
    9.1 10037561 Purpura thrombocytopenic LLT
    9.1 10002034 Anaemia PT
    9.1 10018932 Haemolytic uraemic syndrome PT
    9.1 10024384 Leukopenia PT
    9.1 10029355 Neutropenias HLT
    9.1 10033661 Pancytopenia PT
    9.1 10013505 Disturbance of liver function tests LLT
    9.1 10002218 Anaphylaxis LLT
    9.1 10002425 Angioedemas HLT
    9.1 10015665 Exfoliative dermatitis LLT
    9.1 10020764 Hypersensitivity vasculitis LLT
    9.1 10021015 Hypokalaemia PT
    9.1 10021058 Hypophosphataemia PT
    9.1 10020603 Hypercholesterolaemia PT
    9.1 10020635 Hyperglycaemia PT
    9.1 10020869 Hypertriglyceridaemia PT
    9.1 10043071 Tachycardia PT
    9.1 10034474 Pericardial effusion PT
    9.1 10048642 Lymphocele PT
    9.1 10051055 Deep vein thrombosis PT
    9.1 10037377 Pulmonary embolism PT
    9.1 10025282 Lymphoedema PT
    9.1 10035742 Pneumonitis PT
    9.1 10035598 Pleural effusion PT
    9.1 10015090 Epistaxis PT
    9.1 10037394 Pulmonary haemorrhage PT
    9.1 10000081 Abdominal pain PT
    9.1 10012735 Diarrhoea PT
    9.1 10042128 Stomatitis PT
    9.1 10033645 Pancreatitis PT
    9.1 10000496 Acne PT
    9.1 10037844 Rash PT
    9.1 10003239 Arthralgia PT
    9.1 10031264 Osteonecrosis PT
    9.1 10037032 Proteinuria PT
    9.1 10029164 Nephrotic syndrome PT
    9.1 10030124 Oedema peripheral PT
    9.1 10021519 Impaired healing PT
    9.1 10030095 Oedema PT
    9.1 10037660 Pyrexia PT
    9.1 10005630 Blood lactate dehydrogenase increased PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2018-004012-22 Sponsor Protocol Number: MGL-3196-11 Start Date*: 2019-07-25
    Sponsor Name:Madrigal Pharmaceuticals, Inc.
    Full Title: A Phase 3, Multinational, Double-Blind, Randomized, Placebo-Controlled Study of MGL-3196 (resmetirom) in Patients With Non-Alcoholic Steatohepatitis (NASH) and Fibrosis to Resolve NASH and Reduce P...
    Medical condition: Non-Alcoholic Steatohepatitis (NASH)
    Disease: Version SOC Term Classification Code Term Level
    22.0 10019805 - Hepatobiliary disorders 10053219 Non-alcoholic steatohepatitis PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: HU (Trial now transitioned) DE (Ongoing) FR (Trial now transitioned) AT (Trial now transitioned) ES (Ongoing) BE (Trial now transitioned) GB (GB - no longer in EU/EEA) IT (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2009-015162-57 Sponsor Protocol Number: P06153 Start Date*: 2011-03-02
    Sponsor Name:Schering-Plough Research Institute, a division of Schering Corporation
    Full Title: A Phase 3, 40-Week, Active-Controlled, Double-Blind, Double-Dummy Extension Study of Preladenant in Subjects With Moderate to Severe Parkinson’s Disease (Phase 3, Protocol No. P06153)
    Medical condition: Parkinson's disease
    Disease: Version SOC Term Classification Code Term Level
    14.1 10029205 - Nervous system disorders 10061536 Parkinson's disease PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FI (Completed) GB (Prematurely Ended) AT (Prematurely Ended) ES (Prematurely Ended) CZ (Prematurely Ended) LT (Prematurely Ended) IT (Prematurely Ended) LV (Prematurely Ended) NL (Completed) SE (Prematurely Ended) BG (Completed) PT (Prematurely Ended) PL (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2021-000168-31 Sponsor Protocol Number: M20-621 Start Date*: 2022-12-18
    Sponsor Name:AbbVie Deutschland GmbH & Co. KG
    Full Title: A Phase 3, Randomized, Open-Label Study to Evaluate Safety and Efficacy of Epcoritamab in Combination with R-CHOP compared to R-CHOP in Subjects with Newly Diagnosed Diffuse Large B-Cell Lymphoma (...
    Medical condition: Diffuse Large B-Cell Lymphoma (DLBCL)
    Disease: Version SOC Term Classification Code Term Level
    21.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10012818 Diffuse large B-cell lymphoma PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: SE (Trial now transitioned) DK (Trial now transitioned) ES (Ongoing) HU (Trial now transitioned) DE (Completed) GR (Trial now transitioned) NL (Trial now transitioned) PT (Trial now transitioned) BE (Trial now transitioned) IT (Trial now transitioned) AT (Trial now transitioned) FR (Trial now transitioned) SK (Trial now transitioned) BG (Trial now transitioned) HR (Trial now transitioned) CZ (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2013-002090-21 Sponsor Protocol Number: IM103177 Start Date*: 2016-02-02
    Sponsor Name:Bristol-Myers Squibb International Corporation
    Full Title: Evaluation of Acute Rejection Rates in de novo Renal Transplant Recipients Following Thymoglobulin Induction, CNI-free, Nulojix (belatacept) -based Immunosuppression
    Medical condition: Maintenance of renal transplant recipients.
    Disease: Version SOC Term Classification Code Term Level
    18.1 10021428 - Immune system disorders 10023439 Kidney transplant rejection PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) AT (Completed)
    Trial results: View results
    EudraCT Number: 2019-004302-10 Sponsor Protocol Number: Intercept Start Date*: 2020-08-19
    Sponsor Name:Västra Götalandsregionen, Sahlgrenska University hospital
    Full Title: A randomized controlled open-label multi-center study to assess the efficacy of Tocilizumab in treatment of chronic active antibody-mediated rejection in kidney transplant recipients
    Medical condition: Treatment of chronic active antibody-mediated rejection in kidney transplant recipients
    Disease: Version SOC Term Classification Code Term Level
    20.0 10021428 - Immune system disorders 10023439 Kidney transplant rejection PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: SE (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2013-003296-34 Sponsor Protocol Number: OTX116505 Start Date*: 2014-01-29
    Sponsor Name:GlaxoSmithKline Research & Development Ltd
    Full Title: A Single Blind, Randomised, Placebo Controlled, Repeat Dose, Dose Escalating Study Investigating Safety, Tolerability Pharmacokinetics, Pharmacodynamics and the Beta-Cell Preserving Effect of Oteli...
    Medical condition: NOT1DM is an autoimmune disease. This means that the immune system, the part of the body which usually helps to fight infections, mistakenly attacks cells that produce insulin in the body. Insulin ...
    Disease: Version SOC Term Classification Code Term Level
    18.0 100000004870 10003814 Autoimmune disease, not elsewhere classified LLT
    Population Age: Adolescents, Under 18, Adults Gender: Male, Female
    Trial protocol: BE (Completed)
    Trial results: View results
    EudraCT Number: 2019-001730-34 Sponsor Protocol Number: TX200-KT02 Start Date*: 2020-03-24
    Sponsor Name:Sangamo Therapeutics France SAS
    Full Title: A Multicentre, Open-Label, Single Ascending Dose, Dose-Ranging, Phase I/IIa Study to Evaluate the Safety and Tolerability of an Autologous Antigen-Specific Chimeric Antigen Receptor T Regulatory Ce...
    Medical condition: Prevention of immune mediated allograft rejection in patients with end-stage renal disease (ESRD) who are tissue typed as HLA-A*02 negative and have received a kidney transplant from an HLA-A*02 po...
    Disease: Version SOC Term Classification Code Term Level
    21.1 100000004865 10050436 Prophylaxis against renal transplant rejection LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (GB - no longer in EU/EEA) NL (Trial now transitioned) DE (Completed) BE (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2020-002990-84 Sponsor Protocol Number: MOR208C310 Start Date*: 2021-03-01
    Sponsor Name:MorphoSys AG
    Full Title: A phase 3, multicenter, randomized, double-blind, placebo-controlled trial comparing the efficacy and safety of tafasitamab plus lenalidomide in addition to R-CHOP versus R-CHOP in previously untre...
    Medical condition: Newly-diagnosed high-intermediate and high-risk diffuse large B-cell lymphoma (DLBCL).
    Disease: Version SOC Term Classification Code Term Level
    21.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10012818 Diffuse large B-cell lymphoma PT
    21.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10012820 Diffuse large B-cell lymphoma NOS LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Trial now transitioned) IE (Trial now transitioned) DE (Trial now transitioned) CZ (Trial now transitioned) SK (Trial now transitioned) HU (Trial now transitioned) AT (Trial now transitioned) IT (Trial now transitioned) RO (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2010-018775-17 Sponsor Protocol Number: TRX4_DM_019_EU_10 Start Date*: 2010-07-02
    Sponsor Name:GlaxoSmithKline
    Full Title: DEFEND 2: Durable-Response Therapy Evaluation For Early- or New-Onset Type 1 Diabetes
    Medical condition: Type 1 Diabetes Mellitus
    Disease: Version SOC Term Classification Code Term Level
    14.0 10027433 - Metabolism and nutrition disorders 10012608 Diabetes mellitus insulin-dependent LLT
    Population Age: Adolescents, Under 18, Adults Gender: Male, Female
    Trial protocol: SE (Completed) DE (Prematurely Ended) FI (Completed) GB (Completed) ES (Completed) IT (Completed) DK (Completed) BE (Completed) NL (Completed)
    Trial results: View results
    EudraCT Number: 2016-003778-42 Sponsor Protocol Number: CC-122-DLBCL-002 Start Date*: 2017-07-31
    Sponsor Name:Celgene Corporation
    Full Title: A Phase 1/2 Open-label, Multicenter Study of CC-122 in Combination With R-CHOP-21 for Previously Untreated Poor-Risk (IPI ≥ 3) Diffuse Large B-Cell Lymphoma
    Medical condition: Previously untreated, high-intermediate and high-risk (International Prognostic Index [IPI] ≥ 3) diffuse large B-cell lymphoma (DLBCL).
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Completed) BE (Completed)
    Trial results: View results
    EudraCT Number: 2010-022549-59 Sponsor Protocol Number: TRX4_DM_J20_GER_10 Start Date*: 2011-03-03
    Sponsor Name:Tolerx, Inc.
    Full Title: DEFEND 2A: Durable-Response Therapy Evaluation For Early- or New-Onset Type 1 Diabetes in Adolescents
    Medical condition: Type 1 Diabetes Mellitus
    Disease: Version SOC Term Classification Code Term Level
    12.1 10012608 Diabetes mellitus insulin-dependent LLT
    Population Age: Adolescents, Under 18 Gender: Male, Female
    Trial protocol: DE (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2021-002177-25 Sponsor Protocol Number: 19-255-03 Start Date*: 2021-11-08
    Sponsor Name:Nektar Therapeutics
    Full Title: A Phase 1b/2, Open-label, Multicenter, Dose Escalation and Dose Expansion Study of NKTR-255 in Combination with Cetuximab as a Salvage Regimen for Solid Tumors
    Medical condition: Relapsed or refractory (R/R) head and neck squamous cell carcinoma (HNSCC) or colorectal carcinoma (CRC)
    Disease: Version SOC Term Classification Code Term Level
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10009963 Colon carcinoma recurrent LLT
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10007336 Carcinoma colon recurrent LLT
    22.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10082179 Squamous cell carcinoma of head and neck metastatic LLT
    21.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10060121 Squamous cell carcinoma of head and neck PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Prematurely Ended) ES (Prematurely Ended) IT (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2008-002205-40 Sponsor Protocol Number: OTX115495 (DEFEND-1 EU) Start Date*: 2008-08-29
    Sponsor Name:Tolerx, Inc. [...]
    1. Tolerx, Inc.
    2. GlaxoSmithKline
    Full Title: DEFEND-1: Durable-Response Therapy Evaluation For Early- or New-Onset Type 1 Diabetes
    Medical condition: Otelixizumab is being developed for the treatment of patients with autoimmune T1DM with residual beta cell function (RBCF), with the goal of preserving RBCF in this patient population. There are cu...
    Disease: Version SOC Term Classification Code Term Level
    14.0 10027433 - Metabolism and nutrition disorders 10012608 Diabetes mellitus insulin-dependent LLT
    Population Age: Adolescents, Under 18, Adults Gender: Male, Female
    Trial protocol: SE (Completed) FI (Completed) GB (Completed) DE (Completed) DK (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2006-003579-11 Sponsor Protocol Number: TRX4_DM_004_EU_06 Start Date*: 2007-03-23
    Sponsor Name:TolerRx, Inc.
    Full Title: Tolerability and Safety of Multiple Dose Regimens of TRX4 Anti-CD3 Monoclonal Antibody in Type 1 Diabetes Mellitus
    Medical condition: Type I Diabetes Mellitus
    Disease: Version SOC Term Classification Code Term Level
    8.1 10045228 Type I diabetes mellitus LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: DE (Prematurely Ended) GB (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2021-003855-40 Sponsor Protocol Number: MOR208C115 Start Date*: 2022-03-09
    Sponsor Name:MorphoSys AG
    Full Title: A Phase 1b/2, Open-Label, Multicenter Study to Evaluate the Safety and Pharmacokinetics of a Modified Tafasitamab IV Dosing Regimen Combined with Lenalidomide (LEN) in Patients with Relapsed or Ref...
    Medical condition: Diffuse Large B-Cell Lymphoma (DLBCL)
    Disease: Version SOC Term Classification Code Term Level
    21.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10012818 Diffuse large B-cell lymphoma PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Ongoing) AT (Trial now transitioned) CZ (Trial now transitioned) IT (Trial now transitioned) PL (Trial now transitioned)
    Trial results: (No results available)
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Wed May 07 23:18:34 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA